Hospira, Inc.  

(Public, NYSE:HSP)   Watch this stock  
Find more results for Hospira
-0.74 (-1.32%)
After Hours: 55.47 0.00 (0.00%)
Jul 31, 7:38PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 55.14 - 56.78
52 week 38.11 - 56.78
Open 55.98
Vol / Avg. 2.02M/1.12M
Mkt cap 9.27B
P/E 53.52
Div/yield     -
EPS 1.04
Shares 168.50M
Beta 0.57
Inst. own 93%
Aug 6, 2014
Hospira Inc at Mitsubishi Seattle Healthcare Conference Add to calendar
Jul 30, 2014
Q2 2014 Hospira Earnings Release
Jul 30, 2014
Q2 2014 Hospira Earnings Conference Call - Webcast
May 29, 2014
Hospira presents at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 - Webcast
May 20, 2014
Hospira presents at the UBS 2014 Healthcare Conference - Webcast
May 14, 2014
Hospira at Bank of America Merrill Lynch Health Care Conference - Webcast
May 7, 2014
Hospira Annual Meeting of Shareholders
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 5.48% -0.62%
Operating margin 8.76% -0.78%
EBITD margin - 7.34%
Return on average assets 3.97% -0.41%
Return on average equity 8.96% -0.28%
Employees 17,000 -
CDP Score - 50 E


275 North Field Drive
United States - Map
+1-847-9376472 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Hospira, Inc. (Hospira) is a provider of injectable drugs and infusion technologies. Hospira's portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Hospira conducts operations worldwide and is managed in three reportable segments: Americas; Europe, Middle East and Africa (EMEA), and Asia Pacific (APAC). The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa, and the APAC segment includes Asia, Japan, Australia and New Zealand. In all segments, Hospira sells a line of products, including specialty injectable and other pharmaceuticals and medication management products. In July 2014, Hospira Inc acquired active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd.

Officers and directors

F. Michael Ball Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Thomas E. Werner Chief Financial Officer, Senior Vice President - Finance
Age: 56
Bio & Compensation  - Reuters
David J. Endicott President, Hospira Medical Devices
Age: 49
Bio & Compensation  - Reuters
Kenneth F. Meyers Chief Human Resource Officer, Senior Vice President
Age: 52
Bio & Compensation  - Reuters
Daphne E. Jones Chief Information Officer, Senior Vice President
Age: 56
Bio & Compensation  - Reuters
Sumant Ramachandra M.D., Ph.D. Senior Vice President, Chief Scientific Officer
Age: 45
Bio & Compensation  - Reuters
Richard John Davies Senior Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
John B. Elliot Senior Vice President - International Pharmaceutical Operations
Age: 62
Bio & Compensation  - Reuters
Zena G. Kaufman Senior Vice President - Quality
Age: 57
Bio & Compensation  - Reuters
Brian J. Smith Senior Vice President, Chief Legal Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance